Table 4.

Effect of transplacental arsenic exposure together with postnatal diethylstilbestrol or tamoxifen treatment on hepatic, adrenal, and pulmonary tumors and lymphoma in female CD1 mice

Tumor site and typeGroup (n)
Control (33)Arsenic alone (34)DES alone (33)TAM alone (35)Arsenic + DES (33)Arsenic + TAM (35)
Liver
    Adenoma0 (0%)1 (3%)1 (3%)0 (0%)3 (9%)3 (9%)
    Carcinoma0 (0%)1 (3%)0 (0%)0 (0%)2 (6%)0 (0%)
    Total epithelial tumors0 (0%)2 (6%)1 (3%)0 (0%)4 (12%)3 (9%)
    Hemangioma0 (0%)0 (0%)0 (0%)0 (0%)1 (3%)0 (0%)
    Hemangiosarcoma0 (0%)2 (6%)0 (0%)0 (0%)0 (0%)1 (3%)
    Total tumors any type0 (0%)4 (12%)1 (3%)0 (0%)5 (15%) *4 (11%)
Adrenal cortex
    Adenoma1 (3%)9 (26%) *3 (9%)2 (6%)8 (24%) *7 (20%) *
Lung
    Adenoma5 (15%)7 (21%)3 (9%)2 (6%)2 (6%)3 (9%)
    Adenocarcinoma4 (12%)5 (15%)2 (6%)4 (11%)7 (21%)5 (14%)
    Total tumors any type9 (27%)12 (35%)5 (15%)6 (17%)9 (26%)8 (23%)
Lymphoma10 (30%)2 (6%) *3 (9%) *6 (17%)4 (12%)10 (29%)
  • NOTE: See Table 1 for details. Liver adenoma and carcinoma were hepatocellular in nature with the exception of a cholangiocarcinoma in the arsenic alone group. Total epithelial liver tumor incidence in the arsenic + diethylstilbestrol group approached significance (P = 0.0568) when compared with control.

  • * Significantly different (P < 0.05) from control.